AMRC welcomes Pratia as newest member, strengthening European representation
The Association of Multisite Research Corporations (AMRC) today announces Pratia, one of the largest and most respected site networks, has joined as the association’s fifteenth member. With this addition, AMRC now represents a collective footprint of nearly 500 research sites, almost 8,000 employees, and approximately 1,500 principal investigators across its member companies, globally.
Webinar Summary: Capitol Hill Forecast — What Should MCRCs Prepare For?
Hosted by AMRC, this timely webinar offered insights into the evolving federal policy and funding landscape affecting multisite clinical research corporations (MCRCs), with a strong focus on strategic advocacy and the challenges ahead.
Member Spotlight: Helios on patient-centered oncology care and addressing ‘One-and-Done’
In a recent interview with E.B. McLindon, CEO of Helios Clinical Research and Director at the Association for Multi-Site Research Corporations (AMRC), McLindon shared his perspective on the mindset needed in the research industry
AMRC responds to an FDA consultation
As part of AMRC’s role to advocate for multisite clinical research corporations (MCRC), we responded to the FDA’s consultation: Protocol Deviations for Clinical Investigations of Drugs, Biological Products, and Devices; Guidance for Industry – Draft Guidance.
Why Do Sponsors and CROs Need a Trade Association Dedicated to Multisite Research Corporations?
The clinical trial ecosystem has become increasingly complex, with the number of drugs in development nearly doubling between 2012 and 2022. This growth, coupled with rising patient recruitment demands and the need for diverse trial endpoints, has highlighted the limitations of the traditional site model.
AMRC publishes positioning paper
The traditional clinical trial model, which relies on independent sites and Principal Investigators (PIs), faces significant inefficiencies, including fragmented processes, delayed start-ups, administrative burdens, and high burnout rates. These inefficiencies contribute to trial delays, missed enrollment targets, and increased costs—estimated at $540,000 per day due to lost prescription sales and trial expenses.
AMRC launches
The Association of Multisite Research Corporations (AMRC) has officially launched, marking a transformative step forward in clinical research. This new trade association aims to advance the adoption of multisite clinical research corporations (MCRCs) to enhance efficiency, improve patient safety, and uphold data integrity in clinical trials.
